| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCND2 |
| Uniprot No | Q9NZV8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 406-630aa |
| 氨基酸序列 | VSNFSRIYHQNQRADKRRAQKKARLARIRAAKSGSANAYMQSKRNGLLSNQLQSSEDEQAFVSKSGSSFETQHHHLLHCLEKTTNHEFVDEQVFEESCMEVATVNRPSSHSPSLSSQQGVTSTCCSRRHKKTFRIPNANVSGSHQGSIQELSTIQIRCVERTPLSNSRSSLNAKMEECVKLNCEQPYVTTAIISIPTPPVTTPEGDDRPESPEYSGGNIVRVSAL |
| 预测分子量 | 27.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KCND2(编码Kv4.2钾通道)重组蛋白研究的3篇代表性文献，信息基于已发表的研究概括整理：
---
1. **文献名称**：*Structural basis for gating modulation of Kv4 channel complexes*
**作者**：Huang, C.L., et al.
**摘要内容**：该研究通过冷冻电镜解析了重组Kv4.2通道蛋白(KCND2编码)与辅助亚基KChIP1和DPP6的复合体结构，揭示了这些亚基如何调控Kv4.2的电压敏感性和通道失活机制，为理解神经元动作电位复极化的分子基础提供了结构依据。
2. **文献名称**：*KChIP2 modulates the cell surface expression and gating of Kv4.2-encoded potassium channels*
**作者**：Jerng, H.H., et al.
**摘要内容**：研究利用重组表达系统证明KChIP2(钙调蛋白样蛋白)与Kv4.2的胞内结构域相互作用，显著增加通道在细胞膜的表达量，并减缓通道的失活过程，阐明了辅助亚基在调节Kv4.2功能中的关键作用。
3. **文献名称**：*A novel KCND2 mutation associated with early-onset epilepsy and neurodevelopmental disorders alters channel gating*
**作者**：Singh, B., et al.
**摘要内容**：该研究在癫痫患者中发现KCND2基因的新突变，通过体外重组表达突变体蛋白并进行电生理分析，发现突变导致Kv4.2通道激活阈值改变和电流幅度下降，提示通道功能异常可能参与神经发育障碍的病理机制。
---
**备注**：以上文献为示例，实际引用时请核对具体论文标题、作者及期刊信息，并补充年份、卷号等详细信息。如需最新研究，建议在PubMed或Web of Science中以“KCND2 recombinant protein”“Kv4.2 structure/function”等关键词检索。
KCND2 encodes the Kv4.2 protein, a voltage-gated potassium channel subunit belonging to the Shal (Kv4) family. These channels mediate transient A-type potassium currents (IA), critical for regulating neuronal excitability, action potential repolarization, and dendritic signal integration in the brain. Kv4.2 is predominantly expressed in the cerebellum, hippocampus, and cortex, where it shapes synaptic plasticity, learning, and memory. Functionally, Kv4.2 channels form tetramers, often associating with auxiliary subunits like KChIPs and DPP6/10 to modulate channel kinetics, trafficking, and sensitivity to voltage.
Recombinant KCND2 protein is engineered for in vitro studies to dissect the channel's biophysical properties, structure-function relationships, and pharmacological modulation. Produced via heterologous expression systems (e.g., HEK293 cells, Xenopus oocytes), it enables detailed electrophysiological analyses (patch-clamp) and structural studies (cryo-EM, X-ray crystallography). Researchers use this tool to investigate mutations linked to neurological disorders, including spinocerebellar ataxia (SCA19/22), epilepsy, and autism spectrum disorders. Additionally, it aids in screening potential therapeutics targeting Kv4.2 dysfunction. Studies also explore its role in neuropathic pain and cardiac arrhythmias, given Kv4.2's homology with cardiac Kv channels. By providing a purified, controllable form of the channel, recombinant KCND2 advances mechanistic insights into its physiological and pathological roles.
×
